The quality troubles that Pfizer acquired with Hospira this month are symptoms of an aging, shortage-prone sterile injectables infrastructure that the pharmaceutical industry is preparing to resolve with new, more agile manufacturing facilities.
Pfizer is piloting a modular oral solids manufacturing system that could be adapted for sterile injectables even as other manufacturers are working to resolve the challenges of the aging sterile...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?